ITGR vs. PODD, TFX, GMED, MASI, IART, ATEC, ATRC, OFIX, SRDX, and ANGO
Should you be buying Integer stock or one of its competitors? The main competitors of Integer include Insulet (PODD), Teleflex (TFX), Globus Medical (GMED), Masimo (MASI), Integra LifeSciences (IART), Alphatec (ATEC), AtriCure (ATRC), Orthofix Medical (OFIX), Surmodics (SRDX), and AngioDynamics (ANGO). These companies are all part of the "health care equipment" industry.
Integer (NYSE:ITGR) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Insulet has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
In the previous week, Insulet had 2 more articles in the media than Integer. MarketBeat recorded 10 mentions for Insulet and 8 mentions for Integer. Insulet's average media sentiment score of 1.07 beat Integer's score of 1.05 indicating that Insulet is being referred to more favorably in the news media.
99.3% of Integer shares are owned by institutional investors. 2.0% of Integer shares are owned by company insiders. Comparatively, 0.5% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Insulet received 336 more outperform votes than Integer when rated by MarketBeat users. Likewise, 66.05% of users gave Insulet an outperform vote while only 63.41% of users gave Integer an outperform vote.
Insulet has a net margin of 13.14% compared to Integer's net margin of 6.01%. Insulet's return on equity of 34.06% beat Integer's return on equity.
Integer currently has a consensus target price of $128.00, suggesting a potential upside of 5.44%. Insulet has a consensus target price of $239.44, suggesting a potential upside of 34.52%. Given Insulet's stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Integer.
Integer has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
Summary
Insulet beats Integer on 15 of the 18 factors compared between the two stocks.
Get Integer News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
